Exocrine Pancreatic Insufficiency
Conditions
Keywords
Enzymes, VIOKASE, Bioavailability
Brief summary
EPI leading to maldigestion is a frequent finding in many diseases of the pancreas, such as chronic pancreatitis (CP). Steatorrhea is the most important digestive manifestation in EPI. The current treatment of EPI includes enzyme supplementation with porcine pancreatic enzyme concentrate, consisting mainly of lipase, amylase and protease. An enzyme preparation able to deliver appropriate enzyme levels to the duodenum instead of the mid gut or distal small bowel, would appear to be clinically efficacious for the treatment of steatorrhea in subjects with CP suffering from EPI.
Detailed description
Day of screening: Subjects will undergo screening procedures prior to entry into the study. Day 0: Subjects will be admitted to the facility. Day 1: Subjects will undergo a first perfusion/aspiration procedure. Day 2: Subjects will rest. Day 3: Subjects will undergo a second perfusion/aspiration procedure. Day 4: Subjects will be discharged.
Interventions
DRUGVIOKASE 16
The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.
Sponsors
AAIPharma
Mayo Clinical Services
City Hospital Laboratory Birmingham
Axcan Pharma
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects must have the ability to give informed consent * Female subjects must use a medically acceptable form of birth control and have a negative pregnancy test upon entering the study and not be breast-feeding * Subjects must have medical condition compatible with exocrine pancreatic insufficiency * Subjects must be off therapeutic doses of pancreatic enzyme supplementation prior to study entry day * Subjects must be on omeprazole at least 5 days prior Day 0.
Exclusion criteria
* Subjects with a known hypersensitivity and/or contraindication to VIOKASE®16 or to any non-active component of VIOKASE or to any protein of porcine origin * Subjects with a known hypersensitivity and/or contraindication to omeprazole or to any non-active component of omeprazole * Subjects on enzyme therapy, H2-receptor antagonists, anticholinergics, antispasmodics prior to study entry * Female subjects who are pregnant or lactating * Subjects with acute pancreatitis or acute exacerbations of chronic pancreatic disease * Subjects with a history of solid organ transplant or significant bowel resection between esophagus and pancreas * Subjects who have received an investigational new drug within 30 days prior to entry into the study. * Subjects with a known coagulopathy * Subjects with any abnormal liver function test * Subjects known to have a significant medical and/or mental disease that would compromise the subject's welfare or confound the study results * Subjects who are not on omeprazole at least 5 days prior Day 0
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the Intraduodenal Lipase activity following single dose administration of VIOKASE16 tablets in EPI after a liquid meal. | 4 months |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of the Intraduodenal protease and amylase activities following administration of VIOKASE16 tablets in EPI after a liquid meal. | 4 months |
Countries
United States
Outcome results
None listed